Beta Bionics Inc
NASDAQ:BBNX
Operating Margin
Beta Bionics Inc
Operating Margin represents how efficiently a company is able to generate profit through its core operations.
Higher ratios are generally better, illustrating the company is efficient in its operations and is good at turning sales into profits.
Operating Margin Across Competitors
| Country | Company | Market Cap |
Operating Margin |
||
|---|---|---|---|---|---|
| US |
B
|
Beta Bionics Inc
NASDAQ:BBNX
|
574.3m USD |
-69%
|
|
| US |
|
Abbott Laboratories
NYSE:ABT
|
231.5B USD |
17%
|
|
| US |
|
Intuitive Surgical Inc
NASDAQ:ISRG
|
191.6B USD |
28%
|
|
| US |
|
Boston Scientific Corp
NYSE:BSX
|
153.6B USD |
19%
|
|
| US |
|
Stryker Corp
NYSE:SYK
|
150B USD |
22%
|
|
| IE |
|
Medtronic PLC
NYSE:MDT
|
112.4B USD |
20%
|
|
| DE |
|
Siemens Healthineers AG
XETRA:SHL
|
52B EUR |
14%
|
|
| US |
|
Becton Dickinson and Co
NYSE:BDX
|
49.6B USD |
13%
|
|
| US |
|
Edwards Lifesciences Corp
NYSE:EW
|
45.1B USD |
28%
|
|
| US |
|
IDEXX Laboratories Inc
NASDAQ:IDXX
|
44B USD |
29%
|
|
| US |
|
Resmed Inc
NYSE:RMD
|
37.7B USD |
32%
|
Beta Bionics Inc
Glance View
Beta Bionics, Inc. is a commercial-stage medical device company. The company is headquartered in Irvine, California and currently employs 279 full-time employees. The company went IPO on 2025-01-30. The firm's product, the iLet Bionic Pancreas (iLet), is an insulin delivery device cleared by the United States Food and Drug Administration (FDA) to utilize adaptive closed-loop algorithms to autonomously determine every insulin dose without requiring a user to count carbohydrate intake. iLet is used for the treatment of Type 1 diabetes (T1D). The firm's solutions include iLet for Adults, iLet for Children, Bionic Circle App and iLet Simulator. The firm is in the early stages of developing an insulin pump that is designed to adhere directly to the skin and administer insulin without the need for tubing, commonly known in the diabetes industry as a patch pump. The company is also in the early stages of developing a bihormonal configuration of the iLet.
See Also
Operating Margin represents how efficiently a company is able to generate profit through its core operations.
Higher ratios are generally better, illustrating the company is efficient in its operations and is good at turning sales into profits.
Based on Beta Bionics Inc's most recent financial statements, the company has Operating Margin of -69.5%.
You don't have any saved screeners yet